Alunbrig-话题@MedSci - 梅斯（MedSci）

#Alunbrig#

7篇内容 | 1001人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1678109, encodeId=ccb916e81090a, content=<a href='/topic/show?id=efb323810d' target=_blank style='color:#2F92EE;'>#Alunbrig#</a>, objectTitle=武田制药宣布FDA接受其补充新药申请并给予优先审查，将酪氨酸激酶抑制剂ALUNBRIG用作ALK +转移性非小细胞肺癌的一线治疗, objectType=article, longId=188797, objectId=3aed188e972f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3aed188e972f, replyNumber=0, likeNumber=68, createdTime=2020-04-10, rootId=0, userName=仁者大医, userId=8e886, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3aed188e972f, moduleTitle=武田制药宣布FDA接受其补充新药申请并给予优先审查，将酪氨酸激酶抑制剂ALUNBRIG用作ALK +转移性非小细胞肺癌的一线治疗, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=3aed188e972f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1678111, encodeId=e71a16e81114c, content=<a href='/topic/show?id=efb323810d' target=_blank style='color:#2F92EE;'>#Alunbrig#</a>, objectTitle=FDA批准武田的酪氨酸激酶抑制剂ALUNBRIG（brigatinib），一线治疗ALK阳性的转移性非小细胞肺癌患者, objectType=article, longId=194626, objectId=133519462630, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=133519462630, replyNumber=0, likeNumber=92, createdTime=2020-09-13, rootId=0, userName=仁者大医, userId=8e886, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=133519462630, moduleTitle=FDA批准武田的酪氨酸激酶抑制剂ALUNBRIG（brigatinib），一线治疗ALK阳性的转移性非小细胞肺癌患者, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=133519462630)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1678110, encodeId=c14616e8110da, content=<a href='/topic/show?id=efb323810d' target=_blank style='color:#2F92EE;'>#Alunbrig#</a>, objectTitle=欧盟批准武田的TKI抑制剂ALUNBRIG，用作ALK阳性非小细胞肺癌患者的一线治疗药物, objectType=article, longId=191689, objectId=a505191689b3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a505191689b3, replyNumber=0, likeNumber=66, createdTime=2020-12-12, rootId=0, userName=仁者大医, userId=8e886, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a505191689b3, moduleTitle=欧盟批准武田的TKI抑制剂ALUNBRIG，用作ALK阳性非小细胞肺癌患者的一线治疗药物, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=a505191689b3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1678108, encodeId=79cd16e81088e, content=<a href='/topic/show?id=efb323810d' target=_blank style='color:#2F92EE;'>#Alunbrig#</a>, objectTitle=ALUNBRIG（brigatinib）治疗ALK阳性NSCLC的中长期数据：两年随访展现的优势, objectType=article, longId=183563, objectId=716c183563f0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=716c183563f0, replyNumber=0, likeNumber=61, createdTime=2020-04-17, rootId=0, userName=仁者大医, userId=8e886, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=716c183563f0, moduleTitle=ALUNBRIG（brigatinib）治疗ALK阳性NSCLC的中长期数据：两年随访展现的优势, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=716c183563f0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1678107, encodeId=c2e816e8107c9, content=<a href='/topic/show?id=efb323810d' target=_blank style='color:#2F92EE;'>#Alunbrig#</a>, objectTitle=NICE推荐布加替尼Alunbrig用于治疗非小细胞肺癌, objectType=article, longId=160400, objectId=625016040034, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=625016040034, replyNumber=0, likeNumber=94, createdTime=2019-09-28, rootId=0, userName=仁者大医, userId=8e886, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=625016040034, moduleTitle=NICE推荐布加替尼Alunbrig用于治疗非小细胞肺癌, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=625016040034)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1678106, encodeId=948b16e8106e1, content=<a href='/topic/show?id=efb323810d' target=_blank style='color:#2F92EE;'>#Alunbrig#</a>, objectTitle=欧盟委员会批准ALUNBRIG（brigatinib）治疗ALK+非小细胞肺癌, objectType=article, longId=154589, objectId=7779154589ed, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7779154589ed, replyNumber=0, likeNumber=90, createdTime=2019-10-30, rootId=0, userName=仁者大医, userId=8e886, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7779154589ed, moduleTitle=欧盟委员会批准ALUNBRIG（brigatinib）治疗ALK+非小细胞肺癌, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=7779154589ed)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1678105, encodeId=d55316e810579, content=<a href='/topic/show?id=efb323810d' target=_blank style='color:#2F92EE;'>#Alunbrig#</a>, objectTitle=Takeda的Alunbrig在ALK阳性NSCLC的PFS击败了辉瑞公司的Xalkori, objectType=article, longId=145287, objectId=5cfb14528e84, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5cfb14528e84, replyNumber=0, likeNumber=69, createdTime=2019-06-26, rootId=0, userName=仁者大医, userId=8e886, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5cfb14528e84, moduleTitle=Takeda的Alunbrig在ALK阳性NSCLC的PFS击败了辉瑞公司的Xalkori, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=5cfb14528e84)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

Alunbrig

2020-05-29

仁者大医 (审核中...)

前往app查看评论内容

#Alunbrig#

武田制药宣布FDA接受其补充新药申请并给予优先审查，将酪氨酸激酶抑制剂ALUNBRIG用作ALK +转移性非小细胞肺癌的一线治疗

2020-04-10

仁者大医 (审核中...)

前往app查看评论内容

#Alunbrig#

FDA批准武田的酪氨酸激酶抑制剂ALUNBRIG（brigatinib），一线治疗ALK阳性的转移性非小细胞肺癌患者

2020-09-13

仁者大医 (审核中...)

前往app查看评论内容

#Alunbrig#

欧盟批准武田的TKI抑制剂ALUNBRIG，用作ALK阳性非小细胞肺癌患者的一线治疗药物

2020-12-12

仁者大医 (审核中...)

前往app查看评论内容

#Alunbrig#

ALUNBRIG（brigatinib）治疗ALK阳性NSCLC的中长期数据：两年随访展现的优势

2020-04-17

仁者大医 (审核中...)

前往app查看评论内容

#Alunbrig#

NICE推荐布加替尼Alunbrig用于治疗非小细胞肺癌

2019-09-28

仁者大医 (审核中...)

前往app查看评论内容

#Alunbrig#

欧盟委员会批准ALUNBRIG（brigatinib）治疗ALK+非小细胞肺癌

2019-10-30

仁者大医 (审核中...)

前往app查看评论内容

#Alunbrig#

Takeda的Alunbrig在ALK阳性NSCLC的PFS击败了辉瑞公司的Xalkori

2019-06-26

科室
- - 订阅+
  - 更多科室
工具
服务